Chester A. Mathis, Ph.D.
Chester A. Mathis, Ph.D., is Professor of Radiology, Pharmaceutical Sciences, and Pharmacology at the University of Pittsburgh School of Medicine. He is also Senior Chemist and Director of the University of Pittsburgh Positron Emission Tomography (PET) Facility. Dr. Mathis received a Ph.D. in chemistry from the University of California, Davis in 1979. He conducted postdoctoral research at UC Davis and UC Berkeley in the laboratories of Kenneth Krohn and Thomas Budinger, where he applied radiotracer methods to study biological and medical problems. He was a staff chemist at Lawrence Berkeley National Laboratory from 1984 to 1992, where he worked on the development of radiopharmaceuticals for a variety of PET imaging applications. He joined the faculty of the University of Pittsburgh School of Medicine in 1992.
Dr. Mathis has a long standing interest in applying synthetic radiochemistry techniques to develop PET radiopharmaceuticals to study brain function in vivo. Over the past 20 years, Dr. Mathis focused primarily on the development of radiotracers to image the serotonin and dopamine neuroreceptor systems, as well as agents to evaluate other aspects of normal and abnormal function in the central nervous system using PET imaging techniques. Approximately 10 years ago, Dr. Mathis joined efforts with Dr. William E. Klunk of the Department of Psychiatry at the University of Pittsburgh to devise a PET radiotracer capable of imaging amyloid. This work led to the development of a new class of radiopharmaceutical agents, among which is Pittsburgh Compound-B, to non-invasively assess amyloid load in the living human brain using PET imaging methodology.
John C. Morris, M.D., is the Harvey A. and Dorismae Hacker Friedman Distinguished Professor of Neurology at the Washington University School of Medicine, as well as Professor of Pathology and Immunology and of Physical Therapy. He is Director of the Alzheimer's Disease Research Center, Memory and Aging Project, and Memory Diagnostic Center at the School of Medicine and Barnes-Jewish Hospital, and also is Director of the Center for Aging at Washington University.
A native of Akron, Ohio, Dr. Morris received his medical degree from the University of Rochester School of Medicine and Dentistry in Rochester, New York, in 1974. He then completed his internship at San Francisco General Hospital before entering private practice as a family physician in Fairbanks, Alaska (1975-1976) and then serving as emergency room director at Carlsbad Regional Medical Center in New Mexico (1976-1977). Dr. Morris subsequently completed residency programs in Ohio in medicine (Akron General Medical Center) and neurology (Cleveland Metropolitan General Hospital). He joined the Washington University School of Medicine in 1982 as a postdoctoral fellow in neuropharmacology and was appointed as Instructor in Neurology in 1983. Dr. Morris was named Harvey A. and Dorismae Hacker Friedman Professor of Neurology in 1998 and as Distinguished Professor in 2003.
Dr. Morris is the Principal Investigator for the program project "Healthy Aging and Senile Dementia," and for the Alzheimer's Disease Research Center at Washington University; both are funded by the National Institute on Aging. He also obtained a Leadership Award from the National Institute on Aging for the Center on Aging.
Dr. Morris a member of the National Board of Directors of the Alzheimer's Association. He serves on nine external advisory boards for Alzheimer's Disease Centers at other institutions and as an ad hoc consultant to numerous pharmaceutical and biotechnology companies. Dr. Morris served as a member of the Neuroscience of Aging Review Committee for the National Institute on Aging (Chair, 1999-2000). He is Editor-in-Chief for the specialty journal Alzheimer's Disease and Associated Disorders. He is the author of more than 180 peer-reviewed articles, has contributed numerous review articles, book chapters, and editorials to the medical literature, and was editor for the Handbook of Dementing Illnesses (1994). He has received many honors, including the Distinguished Achievement Citation from his alma mater, Ohio Wesleyan University. He received the Lifetime Achievement Award in recognition of outstanding research from the Alzheimer's Association in July 2004 at the 9th International Conference of Alzheimer's Disease. He received the 2004 MetLife Foundation Award for Medical Research in Alzheimer's Disease. He received the 2005 Potamkin Prize for Research in Pick's, Alzheimer's, and Related Disease from the American Academy of Neurology. He received the 2005 Physician-Scientist Lifetime Achievement Award, Barnes-Jewish Hospital (St. Louis) Foundation.
The focus of Dr. Morris' research and practice is Alzheimer's disease and other neurological disorders associated with aging. Specific research interests include improving the diagnosis and clinicopathological characterization of early-stage Alzheimer's disease, evaluating new drugs for the treatment of dementia, and establishing phenotypes for inherited forms of Alzheimer's disease and other dementias.
Kirk Frey, M.D., Ph.D., is a professor of Neurology and Radiology at the University of Michigan. He received both his M.D. and Ph.D. from the University of Michigan and currently specializes in Nuclear Radiology. His clinical and research interests include movement disorders, Parkinson's disease, brain imaging, and neuropharmacology.